{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T11:07:04Z","timestamp":1792840024277,"version":"4.5.0"},"reference-count":59,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics in Liver Disease"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1016\/j.cld.2023.01.007","type":"journal-article","created":{"date-parts":[[2023,3,8]],"date-time":"2023-03-08T15:21:58Z","timestamp":1678288918000},"page":"483-513","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":33,"title":["Economic Burden and Patient-Reported Outcomes of Nonalcoholic Fatty Liver Disease"],"prefix":"10.1016","volume":"27","author":[{"given":"Maria","family":"Stepanova","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Henry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zobair M.","family":"Younossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cld.2023.01.007_bib1","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1001\/jama.1995.03520250075037","article-title":"Linking clinical variables with health-related quality of life","volume":"1995","author":"Wilson","year":"1995","journal-title":"JAMA"},{"key":"10.1016\/j.cld.2023.01.007_bib3","doi-asserted-by":"crossref","first-page":"S217","DOI":"10.1097\/00005650-198903001-00018","article-title":"Generic and disease-specific measures in assessing health status and quality of life","volume":"27","author":"Patrick","year":"1989","journal-title":"Med Care"},{"key":"10.1016\/j.cld.2023.01.007_bib4","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/1477-7525-8-12","article-title":"A\u00a0review of health utilities across conditions common in paediatric and adult populations","volume":"8","author":"Tarride","year":"2010","journal-title":"Health Qual Life Outcomes"},{"issue":"11","key":"10.1016\/j.cld.2023.01.007_bib5","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.4254\/wjh.v7.i11.1450","article-title":"Non-alcoholic fatty liver disease in 2015","volume":"7","author":"Ahmed","year":"2015","journal-title":"World J Hepatol"},{"issue":"12","key":"10.1016\/j.cld.2023.01.007_bib6","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1007\/s40273-015-0316-5","article-title":"Economic and quality-of-life implications of non-alcoholic fatty liver disease","volume":"33","author":"Younossi","year":"2015","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.cld.2023.01.007_bib7","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.jpsychores.2018.07.004","article-title":"Quality of life in patients with nonalcoholic fatty liver disease: a systematic review","volume":"112","author":"Assimakopoulos","year":"2018","journal-title":"J\u00a0Psychosom Res"},{"issue":"2","key":"10.1016\/j.cld.2023.01.007_bib8","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1136\/gut.45.2.295","article-title":"Development of a disease specific questionnaire to measure health related quality of life in patients with chronic liver disease","volume":"45","author":"Younossi","year":"1999","journal-title":"Gut"},{"issue":"5","key":"10.1016\/j.cld.2023.01.007_bib9","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1111\/j.1365-2036.2009.04061.x","article-title":"Predictors of health-related quality of life in patients with chronic liver disease","volume":"30","author":"Afendy","year":"2009","journal-title":"Aliment Pharmacol Ther"},{"issue":"6","key":"10.1016\/j.cld.2023.01.007_bib10","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1002\/hep.22868","article-title":"Quality of life in adults with nonalcoholic fatty liver disease: baseline data from the nonalcoholic steatohepatitis clinical research network","volume":"49","author":"David","year":"2009","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.cld.2023.01.007_bib11","doi-asserted-by":"crossref","first-page":"e000069","DOI":"10.1136\/bmjgast-2015-000069","article-title":"Reliability and validity of the chronic liver disease questionnaire (CLDQ) in adults with non-alcoholic steatohepatitis (NASH)","volume":"3","author":"Chawla","year":"2016","journal-title":"BMJ Open Gastroenterol"},{"issue":"12","key":"10.1016\/j.cld.2023.01.007_bib12","doi-asserted-by":"crossref","first-page":"2552","DOI":"10.1016\/j.cgh.2019.02.024","article-title":"Reduced patient-reported outcome scores associate with level of fibrosis in patients with nonalcoholic steatohepatitis","volume":"17","author":"Younossi","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"6","key":"10.1016\/j.cld.2023.01.007_bib13","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1016\/j.cgh.2021.07.039","article-title":"Hepatic fat reduction due to resmetirom in patients with nonalcoholic steatohepatitis is associated with improvement of quality of life","volume":"20","author":"Younossi","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"6","key":"10.1016\/j.cld.2023.01.007_bib14","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1111\/j.1365-2036.2007.03426.x","article-title":"Health-related quality of life in patients with non-alcoholic fatty liver disease","volume":"26","author":"Dan","year":"2007","journal-title":"Aliment Pharmacol Ther"},{"issue":"10","key":"10.1016\/j.cld.2023.01.007_bib15","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.14309\/ajg.0000000000000375","article-title":"Patients with nonalcoholic steatohepatitis experience severe impairment of health-related quality of life","volume":"114","author":"Younossi","year":"2019","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cld.2023.01.007_bib16","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s12955-016-0420-z","article-title":"Non-alcoholic fatty liver disease (NAFLD) is associated with impairment of health related quality of life (HRQOL)","volume":"14","author":"Golabi","year":"2016","journal-title":"Health Qual Life Outcomes"},{"key":"10.1016\/j.cld.2023.01.007_bib17","doi-asserted-by":"crossref","first-page":"S111","DOI":"10.1016\/S0168-8278(20)30743-1","article-title":"The clinical and patient reported outcomes (PROs) profile of patients with non-alcoholic fatty liver disease (NAFLD) from real-world practices varies across the world","volume":"73","author":"Younossi","year":"2020","journal-title":"J\u00a0Hepatol"},{"issue":"10","key":"10.1016\/j.cld.2023.01.007_bib18","doi-asserted-by":"crossref","first-page":"2296","DOI":"10.1016\/j.cgh.2021.11.004","article-title":"Clinical and patient-reported outcomes from patients with nonalcoholic fatty liver disease across the world: data from the global non-alcoholic steatohepatitis (NASH)\/non-alcoholic fatty liver disease (NAFLD) registry","volume":"20","author":"Younossi","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"8","key":"10.1016\/j.cld.2023.01.007_bib19","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1111\/liv.13391","article-title":"A\u00a0disease-specific quality of life instrument for non-alcoholic fatty liver disease and non-alcoholic steatohepatitis: CLDQ-NAFLD","volume":"37","author":"Younossi","year":"2017","journal-title":"Liver Int"},{"issue":"10","key":"10.1016\/j.cld.2023.01.007_bib20","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1016\/j.cgh.2019.01.001","article-title":"Validation of chronic liver disease questionnaire for nonalcoholic steatohepatitis in patients with biopsy-proven nonalcoholic steatohepatitis","volume":"17","author":"Younossi","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.cld.2023.01.007_bib21","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1186\/s12955-021-01778-w","article-title":"Health-related quality of life in Chinese population with non-alcoholic fatty liver disease: a national multicenter survey","volume":"19","author":"Huang","year":"2021","journal-title":"Health Qual Life Outcomes"},{"issue":"9","key":"10.1016\/j.cld.2023.01.007_bib22","doi-asserted-by":"crossref","first-page":"2050","DOI":"10.1016\/j.cgh.2021.07.020","article-title":"Obeticholic acid impact on quality of life in patients with nonalcoholic steatohepatitis: REGENERATE 18-month interim analysis","volume":"20","author":"Younossi","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"5","key":"10.1016\/j.cld.2023.01.007_bib23","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1007\/s40271-020-00485-w","article-title":"Development of a patient-reported outcome measure for non-alcoholic steatohepatitis (NASH-CHECK): results of a qualitative study","volume":"14","author":"Doward","year":"2021","journal-title":"Patient"},{"key":"10.1016\/j.cld.2023.01.007_bib24","doi-asserted-by":"crossref","first-page":"21","DOI":"10.3389\/fimmu.2017.00021","article-title":"Role of inflammation in human fatigue: relevance of multidimensional assessments and potential neuronal mechanisms","volume":"8","author":"Karshikoff","year":"2017","journal-title":"Front Immunol"},{"issue":"28","key":"10.1016\/j.cld.2023.01.007_bib25","doi-asserted-by":"crossref","first-page":"3669","DOI":"10.3748\/wjg.v25.i28.3669","article-title":"Importance of fatigue and its measurement in chronic liver disease","volume":"25","author":"Gerber","year":"2019","journal-title":"World J Gastroenterol"},{"issue":"7","key":"10.1016\/j.cld.2023.01.007_bib26","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1007\/s11136-017-1516-6","article-title":"Demonstration of two types of fatigue in subjects with chronic liver disease using factor analysis","volume":"26","author":"Weinstein","year":"2017","journal-title":"Qual Life Res"},{"issue":"3","key":"10.1016\/j.cld.2023.01.007_bib27","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1155\/2006\/624832","article-title":"Fatigue in liver disease: pathophysiology and clinical management","volume":"20","author":"Swain","year":"2006","journal-title":"Can J Gastroenterol"},{"issue":"6","key":"10.1016\/j.cld.2023.01.007_bib28","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1136\/gut.2007.139303","article-title":"Fatigue in non-alcoholic fatty liver disease (NAFLD) is significant and associates with inactivity and excessive daytime sleepiness but not with liver disease severity or insulin resistance","volume":"57","author":"Newton","year":"2008","journal-title":"Gut"},{"issue":"3","key":"10.1016\/j.cld.2023.01.007_bib29","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1111\/jvh.12483","article-title":"Impact of eradicating hepatitis C virus on the work productivity of chronic hepatitis C (CH-C) patients: an economic model from five European countries","volume":"23","author":"Younossi","year":"2016","journal-title":"J\u00a0Viral Hepat"},{"issue":"5","key":"10.1016\/j.cld.2023.01.007_bib30","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1002\/hep.27757","article-title":"Ledipasvir\/sofosbuvir regimens for chronic hepatitis C infection: insights from a work productivity economic model from the United States","volume":"61","author":"Younossi","year":"2015","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.cld.2023.01.007_bib31","doi-asserted-by":"crossref","first-page":"e000106","DOI":"10.1136\/bmjgast-2016-000106","article-title":"Assessment of health utilities and quality of life in patients with non-alcoholic fatty liver disease","volume":"3","author":"Sayiner","year":"2016","journal-title":"BMJ Open Gastroenterol"},{"issue":"12","key":"10.1016\/j.cld.2023.01.007_bib32","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1097\/MLR.0b013e31814848f1","article-title":"US norms for six generic health-related quality-of-life indexes from the National Health Measurement study","volume":"45","author":"Fryback","year":"2007","journal-title":"Med Care"},{"issue":"1","key":"10.1016\/j.cld.2023.01.007_bib33","first-page":"347","article-title":"Cost-effectiveness and potential value of pharmaceutical treatment of nonalcoholic fatty liver disease","volume":"25","author":"Rustgi","year":"2022","journal-title":"J\u00a0Med Econ"},{"key":"10.1016\/j.cld.2023.01.007_bib34","series-title":"Self-reported population health: an international perspective based on EQ-5D","first-page":"19","article-title":"Population norms for the EQ-5D","author":"Janssen","year":"2014"},{"issue":"3","key":"10.1016\/j.cld.2023.01.007_bib35","doi-asserted-by":"crossref","first-page":"100099","DOI":"10.1016\/j.jhepr.2020.100099","article-title":"Health-related quality of life and patient-reported outcome measures in NASH-related cirrhosis","volume":"2","author":"McSweeney","year":"2020","journal-title":"JHEP Rep"},{"issue":"10","key":"10.1016\/j.cld.2023.01.007_bib36","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1016\/j.cgh.2018.12.016","article-title":"Health-related quality of life in nonalcoholic fatty liver disease associates with hepatic inflammation","volume":"17","author":"Huber","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"11","key":"10.1016\/j.cld.2023.01.007_bib37","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1002\/hep4.1581","article-title":"Fatigue and pruritus in patients with advanced fibrosis due to nonalcoholic steatohepatitis: the impact on patient-reported outcomes","volume":"4","author":"Younossi","year":"2020","journal-title":"Hepatol Commun"},{"issue":"5","key":"10.1016\/j.cld.2023.01.007_bib38","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1053\/j.gastro.2020.12.003","article-title":"The association of histologic and noninvasive tests with adverse clinical and patient-reported outcomes in patients with advanced fibrosis due to nonalcoholic steatohepatitis","volume":"160","author":"Younossi","year":"2021","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1016\/j.cld.2023.01.007_bib39","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1002\/hep.28416","article-title":"Weight loss results in significant improvements in quality of life for patients with nonalcoholic fatty liver disease: a prospective cohort study","volume":"63","author":"Tapper","year":"2016","journal-title":"Hepatology"},{"issue":"10","key":"10.1016\/j.cld.2023.01.007_bib40","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1111\/liv.13706","article-title":"Improvement of hepatic fibrosis and patient-reported outcomes in non-alcoholic steatohepatitis treated with selonsertib","volume":"38","author":"Younossi","year":"2018","journal-title":"Liver Int"},{"issue":"10019","key":"10.1016\/j.cld.2023.01.007_bib41","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/S0140-6736(15)00803-X","article-title":"Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study","volume":"387","author":"Armstrong","year":"2016","journal-title":"Lancet"},{"issue":"18","key":"10.1016\/j.cld.2023.01.007_bib42","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1056\/NEJMoa0907929","article-title":"Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis","volume":"362","author":"Sanyal","year":"2010","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.cld.2023.01.007_bib43","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.psym.2018.09.001","article-title":"Psychosocial issues in pediatric nonalcoholic fatty liver disease","volume":"60","author":"Karaivazoglou","year":"2019","journal-title":"Psychosomatics"},{"key":"10.1016\/j.cld.2023.01.007_bib44","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1097\/MCG.0000000000000071","article-title":"Trends in outpatient resource utilizations and outcomes for Medicare beneficiaries with nonalcoholic fatty liver disease","volume":"49","author":"Younossi","year":"2015","journal-title":"J\u00a0Clin Gastroenterol"},{"issue":"3","key":"10.1016\/j.cld.2023.01.007_bib45","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1097\/MCG.0000000000000567","article-title":"Variables associated with inpatient and outpatient resource utilization among Medicare beneficiaries with nonalcoholic fatty liver disease with or without cirrhosis","volume":"51","author":"Sayiner","year":"2017","journal-title":"J\u00a0Clin Gastroenterol"},{"issue":"4","key":"10.1016\/j.cld.2023.01.007_bib46","doi-asserted-by":"crossref","first-page":"562","DOI":"10.14309\/ajg.0000000000000484","article-title":"Disease severity is associated with higher healthcare utilization in nonalcoholic steatohepatitis Medicare patients","volume":"115","author":"Gordon","year":"2020","journal-title":"Am J Gastroenterol"},{"issue":"50","key":"10.1016\/j.cld.2023.01.007_bib47","doi-asserted-by":"crossref","first-page":"e23506","DOI":"10.1097\/MD.0000000000023506","article-title":"Disease severity predicts higher healthcare costs among hospitalized nonalcoholic fatty liver disease\/nonalcoholic steatohepatitis (NAFLD\/NASH) patients in Spain","volume":"99","author":"Romero-Gomez","year":"2020","journal-title":"Medicine (Baltimore)"},{"issue":"6","key":"10.1016\/j.cld.2023.01.007_bib48","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/j.numecd.2020.02.016","article-title":"Healthcare resource utilization and costs of nonalcoholic steatohepatitis patients with advanced liver disease in Italy","volume":"30","author":"Petta","year":"2020","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"10.1016\/j.cld.2023.01.007_bib49","doi-asserted-by":"crossref","first-page":"S32","DOI":"10.1016\/S0168-8278(18)30282-4","article-title":"Substantial comorbidities and rising economic burden in real-world non-alcoholic fatty liver disease (NAFLD)\/non-alcoholic steatohepatitis (NASH) patients with compensated cirrhosis (CC): a large German claims database study","volume":"68","author":"Canbay","year":"2018","journal-title":"J\u00a0Hepatol"},{"issue":"7","key":"10.1016\/j.cld.2023.01.007_bib50","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1016\/j.cgh.2019.10.023","article-title":"Healthcare costs of patients with biopsy-confirmed nonalcoholic fatty liver disease are nearly twice those of matched controls","volume":"18","author":"Hagstr\u00f6m","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"5","key":"10.1016\/j.cld.2023.01.007_bib51","doi-asserted-by":"crossref","first-page":"100142","DOI":"10.1016\/j.jhepr.2020.100142","article-title":"Cost of non-alcoholic steatohepatitis in Europe and the USA: The GAIN study","volume":"2","author":"O\u2019Hara","year":"2020","journal-title":"JHEP Rep"},{"issue":"5","key":"10.1016\/j.cld.2023.01.007_bib52","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1002\/hep.28785","article-title":"The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe","volume":"64","author":"Younossi","year":"2016","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.cld.2023.01.007_bib53","doi-asserted-by":"crossref","first-page":"283","DOI":"10.2337\/dc19-1113","article-title":"Economic and clinical burden of nonalcoholic steatohepatitis in patients with type 2 diabetes in the U.S","volume":"43","author":"Younossi","year":"2020","journal-title":"Diabetes Care"},{"issue":"2","key":"10.1016\/j.cld.2023.01.007_bib54","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1002\/hep.30254","article-title":"Burden of illness and economic model for patients with nonalcoholic steatohepatitis in the United States","volume":"69","author":"Younossi","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2023.01.007_bib55","author":"World Health Organization (WHO)"},{"key":"10.1016\/j.cld.2023.01.007_bib56","author":"World Health Organization (WHO)"},{"issue":"9","key":"10.1016\/j.cld.2023.01.007_bib57","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1111\/hepr.13535","article-title":"Modelling the economic and clinical burden of non-alcoholic steatohepatitis in East Asia: data from Hong Kong","volume":"50","author":"Tampi","year":"2020","journal-title":"Hepatol Res"},{"issue":"1","key":"10.1016\/j.cld.2023.01.007_bib58","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1186\/s12876-021-01720-w","article-title":"Economic burden of non-alcoholic steatohepatitis with significant fibrosis in Thailand","volume":"21","author":"Phisalprapa","year":"2021","journal-title":"BMC Gastroenterol"},{"issue":"6","key":"10.1016\/j.cld.2023.01.007_bib59","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1111\/liv.14825","article-title":"Disease burden and economic impact of diagnosed non-alcoholic steatohepatitis in five European countries in 2018: a cost-of-illness analysis","volume":"41","author":"Schattenberg","year":"2021","journal-title":"Liver Int"},{"key":"10.1016\/j.cld.2023.01.007_bib60","first-page":"1","article-title":"Hypothetical treatment of patients with non-alcoholic steatohepatitis: potential impact on important clinical outcomes","volume":"1","author":"Younossi","year":"2019","journal-title":"Liver Int"}],"container-title":["Clinics in Liver Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1089326123000077?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1089326123000077?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T18:02:08Z","timestamp":1761069728000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1089326123000077"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":59,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["S1089326123000077"],"URL":"https:\/\/doi.org\/10.1016\/j.cld.2023.01.007","relation":{},"ISSN":["1089-3261"],"issn-type":[{"value":"1089-3261","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Economic Burden and Patient-Reported Outcomes of Nonalcoholic Fatty Liver Disease","name":"articletitle","label":"Article Title"},{"value":"Clinics in Liver Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cld.2023.01.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}